company background image
AGEN logo

Agenus NasdaqCM:AGEN Stock Report

Last Price

US$0.58

Market Cap

US$233.1m

7D

3.2%

1Y

-60.0%

Updated

28 Mar, 2024

Data

Company Financials +

AGEN Stock Overview

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally.

AGEN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Agenus Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Agenus
Historical stock prices
Current Share PriceUS$0.58
52 Week HighUS$2.13
52 Week LowUS$0.48
Beta1.27
1 Month Change-25.43%
3 Month Change-29.94%
1 Year Change-60.00%
3 Year Change-79.79%
5 Year Change-80.14%
Change since IPO-99.84%

Recent News & Updates

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Recent updates

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22
Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09
News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04
A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10
Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Oct 12

Agenus New Trials Set It Up For The Long Haul

Sep 27

Agenus: It's Always Tomorrow

Sep 16

Agenus GAAP EPS of -$0.17, revenue of $20.93M

Aug 09

Agenus: Successfully Pulled Itself Away From Disaster

Jul 04

Agenus: Not Quite Enough

Apr 19

Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Mar 06
Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Agenus: Making Another Effort With The FDA

Jan 25

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11
Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

FDA accepts Agenus' balstilimab BLA under "priority review" status

Jun 17

Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy

May 26

Agenus shares fall after Q1 topline miss

May 06

Is Agenus Inc. (NASDAQ:AGEN) Popular Amongst Institutions?

Feb 15
Is Agenus Inc. (NASDAQ:AGEN) Popular Amongst Institutions?

Shareholder Returns

AGENUS BiotechsUS Market
7D3.2%0.9%0.2%
1Y-60.0%11.0%28.1%

Return vs Industry: AGEN underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: AGEN underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is AGEN's price volatile compared to industry and market?
AGEN volatility
AGEN Average Weekly Movement15.1%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: AGEN's share price has been volatile over the past 3 months.

Volatility Over Time: AGEN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1994389Garo Armenhttps://www.agenusbio.com

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.

Agenus Inc. Fundamentals Summary

How do Agenus's earnings and revenue compare to its market cap?
AGEN fundamental statistics
Market capUS$233.09m
Earnings (TTM)-US$245.97m
Revenue (TTM)US$156.31m

1.6x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AGEN income statement (TTM)
RevenueUS$156.31m
Cost of RevenueUS$237.68m
Gross Profit-US$81.37m
Other ExpensesUS$164.61m
Earnings-US$245.97m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.59
Gross Margin-52.05%
Net Profit Margin-157.36%
Debt/Equity Ratio-8.7%

How did AGEN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.